Welcome to our dedicated page for Ani Pharmaceutic SEC filings (Ticker: ANIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ANI Pharmaceuticals, Inc. filings document financial results, operating updates, governance matters, and material events for its Rare Disease, Generics, and Brands businesses. Form 8-K reports furnish earnings releases, preliminary results, guidance updates, Regulation FD investor presentations, and corporate changes such as independent auditor matters.
ANI proxy filings cover shareholder voting items, board governance, executive compensation, equity awards, and related governance disclosures. The filing record also provides formal context for product and business risks tied to biopharmaceutical development, FDA-regulated generic launches, branded products, commercialization, manufacturing, and capital actions.
ANI Pharmaceuticals senior vice president, general counsel and secretary Meredith Cook reported an open-market sale of 500 shares of Common Stock. The shares were sold at an average price of $82.03 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025. After this sale, Cook directly held 77,890 shares of ANI Pharmaceuticals common stock.
Thoma Jeanne reported acquisition or exercise transactions in this Form 4 filing.
ANI Pharmaceuticals director Jeanne Thoma received a new equity grant. She was awarded 4,357 shares of ANI Pharmaceuticals common stock as a restricted stock award, with no cash paid per share. After this grant, she directly holds 27,762 common shares.
The restricted stock award will vest in full on May 21, 2027, meaning she will gain full ownership of these shares on that date if the vesting conditions are satisfied.
TANNENBAUM RENEE P reported acquisition or exercise transactions in this Form 4 filing.
ANI Pharmaceuticals director Renee P. Tannenbaum received a grant of 4,357 shares of common stock as a restricted stock award on May 21, 2026. The award carries no purchase price and will vest in full on May 21, 2027, if conditions are met.
Following this compensation-related grant, Tannenbaum directly holds 29,514 shares of ANI Pharmaceuticals common stock. This is a routine equity award to a board member rather than an open-market transaction.
Pera Antonio R reported acquisition or exercise transactions in this Form 4 filing.
ANI Pharmaceuticals director Antonio R. Pera received a grant of 4,357 shares of Common Stock as a restricted stock award. The award was granted at no cash cost to him and is part of his equity compensation.
The restricted shares are scheduled to vest in full on May 21, 2027, meaning they must be held until that date before becoming fully transferable. Following this grant, Pera directly holds a total of 27,017 shares of ANI Pharmaceuticals Common Stock.
Leonard Matthew J reported acquisition or exercise transactions in this Form 4 filing.
ANI Pharmaceuticals director Matthew J. Leonard received a grant of 4,357 shares of common stock as a restricted stock award. The award was granted at no cash cost per share and is part of his equity-based compensation. These restricted shares will vest in full on May 21, 2027, meaning he must remain eligible through that date to receive them outright. After this grant, Leonard directly holds a total of 11,221 shares of ANI Pharmaceuticals common stock, indicating this is a relatively small, routine compensation-related award rather than a market purchase or sale.
ANI Pharmaceuticals director Thomas Haughey reported both a stock grant and a share sale. On May 21, 2026, he acquired 4,357 shares of Common Stock as a restricted stock award that will vest in full on May 21, 2027. On June 8, 2026, he sold 2,000 Common Stock shares in an open-market transaction at $80.88 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 9, 2026. After these transactions, he directly holds 38,878 Common Stock shares.
ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported an option exercise and share sale. He exercised stock options to acquire 3,312 shares of common stock at $49.51 per share, then sold 3,312 shares in an open-market transaction at $80.00 per share. The transactions were completed under a pre-arranged Rule 10b5-1 trading plan. After these trades, Carey directly owns 180,393 shares of ANI Pharmaceuticals common stock.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 notice reporting the proposed sale of 11,862 shares of Common Stock in connection with affiliate dispositions. The filing lists 3,312 shares from an exercise of stock options dated 06/05/2026 and 8,550 shares from restricted stock awards dated 03/31/2018.
The notice shows an aggregate value field of $939,470.40 and a separate numeric field 22,734,618; the filing's exact labels for those figures are presented in the excerpt.
ANI Pharmaceuticals, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on May 21, 2026. Stockholders approved all proposals, including electing seven directors to serve until the 2027 annual meeting and ratifying Ernst & Young LLP as independent auditor for the year ending December 31, 2026.
Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers and chose to hold this advisory vote every one year. In addition, they approved the company’s Amended and Restated 2022 Stock Incentive Plan, which governs equity-based compensation, with the full plan text filed as an exhibit.